# High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

> **NCT00936936** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 64 (actual)

## Conditions studied

- Testicular Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Melphalan
- **DRUG:** Carboplatin
- **DRUG:** Mesna
- **DRUG:** Ifosfamide
- **DRUG:** Etoposide
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT00936936
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-02
- **Primary completion:** 2024-01-11
- **Final completion:** 2024-01-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00936936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00936936, "High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00936936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*